{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:37:03Z","timestamp":1777289823167,"version":"3.51.4"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40272-026-00743-8","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T15:59:48Z","timestamp":1771257588000},"page":"321-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Puzolcabtagene Autoleucel: Pediatric First Approval"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1028-8594","authenticated-orcid":false,"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"743_CR1","unstructured":"Chongqing Precision Biotech. China approves first CAR-T Therapy specifically for pediatric R\/R B-ALL: Chongqing Precision Biotech\u2019s puzolcabtagene autoleucel injection (pCAR-19B) receives NMPA approval [media release]. 7 Nov 2025. https:\/\/en.precision-biotech.com\/2025\/217.html."},{"key":"743_CR2","unstructured":"Chongqing Precision Biotech. Fields & pipeline. 2026. https:\/\/en.precision-biotech.com\/FIELDS%20AND%20PIPELINE.html. Accessed 14 Jan 2026."},{"issue":"1","key":"743_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10(1):210.","journal-title":"Signal Transduct Target Ther"},{"issue":"Suppl 1","key":"743_CR4","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1182\/blood-2022-162134","volume":"140","author":"ZY Hong","year":"2022","unstructured":"Hong ZY, Yang Z, Zhou XX, et al. The safety and efficacy of p CAR-19B, a Scfv humanized CD19-directed CAR-T for patients with relapsed\/refactory (R\/R) CD19+ B-ALL [abstract]. Blood. 2022;140(Suppl 1):4625\u20136.","journal-title":"Blood"},{"key":"743_CR5","unstructured":"Chongqing Precision Biotech. Puzolcabtagene autoleucel injection: Chinese prescribing information. 2025. Accessed 15 Jan 2026."},{"key":"743_CR6","unstructured":"Chongqing Precision Biotech. pCAR-19B, independently developed by Precision Biotech, granted Breakthrough Therapy designation by the NMPA as the first CAR-T product for the treatment of childhood leukemia in China [media release]. 10 Nov 2023. https:\/\/en.precision-biotech.com\/2023\/163.html."},{"issue":"Suppl 1","key":"743_CR7","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1182\/blood-2024-206408","volume":"144","author":"RD Zhang","year":"2024","unstructured":"Zhang RD, Cao Y, Zhu XF, et al. A phase 2 clinical trial of anti-CD19 CAR-T (pCAR-19B) in Chinese pediatric and young adult with relapsed\/refractory (R\/R) CD19+B-ALL: the first pivotal study in an Asian population [abstract]. Blood. 2024;144(Suppl 1):4205\u20136.","journal-title":"Blood"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00743-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00743-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00743-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T10:48:40Z","timestamp":1777286920000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00743-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["743"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00743-8","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Y. Syed is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}